140 related articles for article (PubMed ID: 23197543)
1. Quantification in molecular ultrasound imaging: a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft.
Sugimoto K; Moriyasu F; Negishi Y; Hamano N; Oshiro H; Rognin NG; Yoshida T; Kamiyama N; Aramaki Y; Imai Y
J Ultrasound Med; 2012 Dec; 31(12):1909-16. PubMed ID: 23197543
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
[TBL] [Abstract][Full Text] [Related]
4. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
5. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M
Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735
[TBL] [Abstract][Full Text] [Related]
6. Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
Baron Toaldo M; Salvatore V; Marinelli S; Palamà C; Milazzo M; Croci L; Venerandi L; Cipone M; Bolondi L; Piscaglia F
Mol Imaging Biol; 2015 Feb; 17(1):29-37. PubMed ID: 25082536
[TBL] [Abstract][Full Text] [Related]
7. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
8. Improved Detection of preclinical Colorectal Liver Metastases by High Resolution Ultrasound including Molecular Ultrasound Imaging using the targeted Contrast Agent BR55.
Hackl C; Schacherer D; Anders M; Wiedemann LM; Mohr A; Schlitt HJ; Stroszczynski C; Tranquart F; Jung EM
Ultraschall Med; 2016 Jun; 37(3):290-6. PubMed ID: 27112624
[TBL] [Abstract][Full Text] [Related]
9. Six-Transmembrane Epithelial Antigen of the Prostate-1 (STEAP-1)-Targeted Ultrasound Imaging Microbubble Improves Detection of Prostate Cancer In Vivo.
Yuan Y; Liu Y; Zhu XM; Hu J; Zhao CY; Jiang F
J Ultrasound Med; 2019 Feb; 38(2):299-305. PubMed ID: 30027616
[TBL] [Abstract][Full Text] [Related]
10. Dual-Targeted Microbubbles Specific to Integrin αVβ3 and Vascular Endothelial Growth Factor Receptor 2 for Ultrasonography Evaluation of Tumor Angiogenesis.
Yuan HX; Wang WP; Wen JX; Lin LW; Exner AA; Guan PS; Chen XJ
Ultrasound Med Biol; 2018 Jul; 44(7):1460-1467. PubMed ID: 29706409
[TBL] [Abstract][Full Text] [Related]
11. [Value of ultrasound-targeted vascular endothelial growth factor receptor-2 in non-invasive monitoring of anti-angiogenic response in nude mice with subcutaneous xenograft model].
Wang L; Lu YH; Wang TY
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):856-860. PubMed ID: 33113627
[No Abstract] [Full Text] [Related]
12. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
[TBL] [Abstract][Full Text] [Related]
13. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
14. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
[TBL] [Abstract][Full Text] [Related]
15. Influence of repetitive contrast agent injections on functional and molecular ultrasound measurements.
Rix A; Palmowski M; Gremse F; Palmowski K; Lederle W; Kiessling F; Bzyl J
Ultrasound Med Biol; 2014 Oct; 40(10):2468-75. PubMed ID: 25023096
[TBL] [Abstract][Full Text] [Related]
16. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
[TBL] [Abstract][Full Text] [Related]
17. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38).
Bzyl J; Lederle W; Rix A; Grouls C; Tardy I; Pochon S; Siepmann M; Penzkofer T; Schneider M; Kiessling F; Palmowski M
Eur Radiol; 2011 Sep; 21(9):1988-95. PubMed ID: 21562807
[TBL] [Abstract][Full Text] [Related]
18. Time-intensity-based quantification of vascularity with single-level dynamic contrast-enhanced ultrasonography: a pilot animal study.
Li J; Dong BW; Yu XL; Wang XH; Li CF
J Ultrasound Med; 2005 Jul; 24(7):975-83. PubMed ID: 15972712
[TBL] [Abstract][Full Text] [Related]
19. Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma.
Wei S; Fu N; Sun Y; Yang Z; Lei L; Huang P; Yang B
Ultrasound Med Biol; 2014 Jun; 40(6):1250-9. PubMed ID: 24613557
[TBL] [Abstract][Full Text] [Related]
20. Image fusion of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) using volume navigation for detection, characterization and planning of therapeutic interventions of liver tumors.
Rennert J; Georgieva M; Schreyer AG; Jung W; Ross C; Stroszczynski C; Jung EM
Clin Hemorheol Microcirc; 2011; 49(1-4):67-81. PubMed ID: 22214679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
